FIELD: medicine.
SUBSTANCE: TGF-β antagonist is introduced, which is an antibody containing the VH-domain of PET1073G12 (SEQ ID NO: 2) and the VL-domain of PET1073G12 (SEQ ID NO: 7). Introduction is carried out within 72 hours from the onset of myocardial ischemia.
EFFECT: reduced fibrosis, improved remodeling and myocardial function.
20 cl, 2 tbl, 30 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STRUCTURED ANTI-TGF-BETA ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | 2014 |
|
RU2681502C2 |
| NUETRALISING ANTIBODIES AGAINST GDF-8 AND THEIR APPLICATION | 2003 |
|
RU2360925C2 |
| TREATING OSTEOARTHRITIS AND PAIN | 2012 |
|
RU2563830C2 |
| HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
| ISOLATED HUMANIZED PROTEIN BINDING TO HUMAN GLYCOPROTEIN VI, ISOLATED ANTIBODY BINDING TO HUMAN GLYCOPROTEIN VI | 2018 |
|
RU2778884C2 |
| ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2739946C2 |
| PROTEIN BOUND WITH HUMAN GLYCOPROTEIN, COMPOSITION, PHARMACEUTICAL COMPOSITION, EXPRESSION VECTOR | 2016 |
|
RU2773819C2 |
| INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
